Cytokine Release Syndrome Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Incyte Corporation, Swedish Orphan Biovitrum (sobi), Genentech

DelveInsight's "Cytokine Release Syndrome Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of cytokine release syndrome, historical and forecasted epidemiology as well as the cytokine release syndrome market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock key insights into the Cytokine Release Syndrome Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Cytokine Release Syndrome Therapeutics Market Outlook- https://www.delveinsight.com/sample-request/cytokine-release-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Cytokine Release Syndrome Market Report
• In April 2025, Hoffmann-La Roche announced a phase II Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
• In April 2025. Ontario Clinical Oncology Group conducted a phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to improve the tolerability and safety of elranatamab in patients with relapsed and/or refractory multiple myeloma by evaluating an outpatient and intermittent dosing strategy.
• In 2023, according to DelveInsight's estimates, CRS cases in the United States accounted for roughly 30% of the total incidence cases (7MM).
• DelveInsight's consultant estimates that approximately 30% of total CRS cases in the United States, resulted from treatment with CAR-T therapies, in 2023.
• Based on Grade-specific incidence, Grade 3-4 cases constituted approximately 18% of total incident CRS cases, in 2023, in the 7MM.
• Among the EU4 and the UK, Germany had the highest incidence of cases of CRS, followed by France.
• The leading Cytokine Release Syndrome Companies such as Incyte Corporation, Swedish Orphan Biovitrum (sobi), Genentech, and others.
• Promising Cytokine Release Syndrome Pipeline Therapies such as CTO1681 10 μg, Itacitinib, Itolizumab IV infusion, Ruxolitinib, Canakinumab, Anakinra and others.

Stay ahead in the competitive landscape of the Cytokine Release Syndrome Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Cytokine Release Syndrome Treatment Market Size- https://www.delveinsight.com/sample-request/cytokine-release-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cytokine Release Syndrome Epidemiology Segmentation in the 7MM
• Cytokine Release Syndrome Prevalence
• Age-Specific Cytokine Release Syndrome Prevalence
• Gender-Specific Cytokine Release Syndrome Prevalence
• Diagnosed and Treatable Cases of Cytokine Release Syndrome

Download the report to understand which factors are driving Cytokine Release Syndrome epidemiology trends @ Cytokine Release Syndrome Prevalence- https://www.delveinsight.com/sample-request/cytokine-release-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cytokine Release Syndrome Marketed Drugs
• ACTEMRA/ROACTEMRA (tocilizumab): Genentech
Tocilizumab is a first-in-class anti-IL-6 receptor (aIL-6R) therapy. ACTEMRA/ROACTEMRA is available in both subcutaneous (SC) and intravenous (IV) formulations. In August 2017, the US FDA approved ACTEMRA (tocilizumab) intravenous injection to treat CAR T-cell-induced severe or life-threatening CRS in patients 2 years and older.

Cytokine Release Syndrome Emerging Drugs
• Itacitinib: Incyte Corporation
Itacitinib is a potent, orally bioavailable, and highly selective inhibitor of Janus kinase (JAK)-1, which mediates the signaling of several inflammatory cytokines. In December 2018, Innovent Biologics (Innovent) and Incyte, through their respective subsidiaries, entered into a strategic collaboration agreement for three clinical-stage product candidates discovered and developed by Incyte-pemigatinib (FGFR1/2/3 inhibitor), itacitinib (JAK1 inhibitor), and parsaclisib (PI3Kδ inhibitor).

• KINERET (anakinra): Swedish Orphan Biovitrum (sobi)
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist protein. It is administered through the subcutaneous route and is approved to treat rheumatoid arthritis and cryopyrin-associated periodic syndromes (CAPS). Kite Pharma is developing anakinra in axicabtagene ciloleucel therapy to reduce the occurrence of the side effects-CRS-and neurologic toxicities with relapsed or refractory non-Hodgkin lymphoma (NHL). The company is investigating this combination in a Phase II clinical trial.

To learn more about Cytokine Release Syndrome treatment guidelines, visit @ Cytokine Release Syndrome Market Drivers and Barriers- https://www.delveinsight.com/sample-request/cytokine-release-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cytokine Release Syndrome Companies
Incyte Corporation, Swedish Orphan Biovitrum (sobi), Genentech, and others.

Cytokine Release Syndrome Market Outlook
The report's outlook on the Cytokine Release Syndrome market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Cytokine Release Syndrome therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Cytokine Release Syndrome drug and late-stage pipeline therapy.

Cytokine Release Syndrome Drugs Uptake
The drug chapter of the Cytokine Release Syndrome report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Cytokine Release Syndrome.

Explore the dynamics of the Cytokine Release Syndrome Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Cytokine Release Syndrome Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/cytokine-release-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Cytokine Release Syndrome Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Cytokine Release Syndrome Companies- Incyte Corporation, Swedish Orphan Biovitrum (sobi), Genentech, and others.
• Cytokine Release Syndrome Pipeline Therapies- CTO1681 10 μg, Itacitinib, Itolizumab IV infusion, Ruxolitinib, Canakinumab, Anakinra and others.
• Cytokine Release Syndrome Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Cytokine Release Syndrome Unmet Needs, KOL's views, Analyst's views, Cytokine Release Syndrome Market Access and Reimbursement

To know more about Cytokine Release Syndrome Companies working in the treatment market, visit @ Cytokine Release Syndrome Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/cytokine-release-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Cytokine Release Syndrome Market Report Introduction
3. Cytokine Release Syndrome (CRS) Market Overview at a Glance
4. Executive Summary of Cytokine Release Syndrome (CRS)
5. Key Events
6. Cytokine Release Syndrome Epidemiology and Market Methodology
7. Cytokine Release Syndrome Disease Background and Overview
8. Cytokine Release Syndrome Patient Journey
9. Cytokine Release Syndrome Epidemiology and Patient Population
10. Cytokine Release Syndrome Marketed Therapies
11. Cytokine Release Syndrome Emerging Drugs
12. Cytokine Release Syndrome (CRS) 7 Major Market Analysis
13. Cytokine Release Syndrome Market Access and Reimbursement
14. Cytokine Release Syndrome KOL Views
15. Cytokine Release Syndrome SWOT Analysis
16. Cytokine Release Syndrome Unmet needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cardiac Implantable Electronic Devices Market- https://www.delveinsight.com/report-store/implantable-cardiac-monitors-market
Sleep Tech Devices Market- https://www.delveinsight.com/report-store/sleep-tech-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Positive Airway Pressure Device Market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Urea Cycle Disorders Market- https://www.delveinsight.com/report-store/urea-cycle-disorders-market
Testicular Neoplasm Market- https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.